Form 4: Bausch + Lomb Director Sarah Kavanagh Receives Annual Equity Grant

Bausch + Lomb Corporation's Director, Sarah B. Kavanagh, was granted 20,338 restricted share units as part of her annual compensation, increasing her total beneficial ownership to 53,699 common shares.

Summary

• Sarah B. Kavanagh, a Director of Bausch + Lomb Corporation (BLCO), acquired 20,338 common shares through an annual grant of restricted share units (RSUs).
• The transaction date for this acquisition was May 27, 2025.
• The RSUs were granted at a price of $0, as is typical for equity compensation grants.
• Following this transaction, Ms. Kavanagh's total beneficial ownership in Bausch + Lomb Corporation stands at 53,699 common shares.
• The RSUs were granted under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, as amended and restated.
• These RSUs are scheduled to vest immediately prior to the next annual meeting of shareholders.

Sentiment

Score: 7

Explanation: The filing indicates a routine equity grant to a non-employee director, which is a positive for aligning management interests with shareholders, but does not represent a significant new development for the company's operations or financial performance, thus having a neutral to slightly positive market sentiment.

Positives

• The grant of restricted share units to a non-employee director aligns the director's interests with those of the shareholders, as their compensation becomes tied to the company's stock performance.
• This is a routine and expected form of compensation for non-employee directors, indicating stable corporate governance practices regarding executive and director remuneration.

Future Outlook

The restricted share units granted to Director Sarah B. Kavanagh are scheduled to vest immediately prior to the next annual meeting of shareholders, indicating a future conversion of these units into common shares.

Management Comments

• "Reflects the annual grant of restricted share units ('RSUs') to non-employee directors under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, as amended and restated."
• "Vested RSUs are settled in common shares, no par value, of Bausch + Lomb Corporation."
• "The RSUs are scheduled to vest immediately prior to the next annual meeting of shareholders."

Industry Context

The practice of compensating non-employee directors with equity, such as restricted share units, is a common and widely accepted practice across various industries for publicly traded companies. This method helps align the interests of the board members with the long-term performance of the company and its shareholders.

Comparison to Industry Standards

• The grant of restricted share units to non-employee directors is a standard compensation practice observed across a wide range of public companies, including those in the healthcare and pharmaceutical sectors like Johnson & Johnson, Abbott Laboratories, and Medtronic, which also utilize equity-based incentives to align director interests with shareholder value.
• The vesting schedule, tied to the next annual meeting, is also a common approach for annual director equity grants, ensuring continued engagement and oversight.

Corporate Governance

Related Party Transactions

• The grant of restricted share units to Sarah B. Kavanagh, a director of Bausch + Lomb Corporation, constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with those of the shareholders, potentially encouraging decisions that enhance long-term shareholder value.
• Employees: While not directly impacting employees, the compensation structure for directors can reflect the overall compensation philosophy of the company.

Next Steps

• The granted restricted share units are scheduled to vest immediately prior to the next annual meeting of shareholders, at which point they will be settled in common shares.

Key Dates

Keywords

Bausch + Lomb, BLCO, Form 4, insider transaction, restricted share units, RSU, director compensation, equity grant, corporate governance